Christine Bowman
About Christine Bowman
Christine Bowman is an Associate Director at Arcus Biosciences, where she leads inflammation and immuno-oncology programs. She has a strong background in biochemistry and has worked in various research roles, including positions at Regeneron Pharmaceuticals and Columbia University.
Work at Arcus Biosciences
Christine Bowman serves as Associate Director at Arcus Biosciences, a position she has held since 2016. In this role, she is responsible for delivering primary cell in vitro assays and murine in vivo models to support candidate selection and regulatory filings. She leads inflammation and immuno-oncology programs, focusing on target validation through Investigational New Drug (IND) applications. Christine collaborates with cross-functional teams, including Biology, Translational Science, Bioinformatics, Protein Therapeutics, Pre-Clinical, and Clinical teams, to align on program goals and coordinate early targets for new programs.
Education and Expertise
Christine Bowman holds a Doctor of Philosophy (Ph.D.) in Biochemistry from Albert Einstein College of Medicine, where she studied from 2009 to 2013. Prior to her Ph.D., she earned a Bachelor of Science (B.S.) in Structural Biology and Biophysics, as well as Molecular and Cell Biology from the University of Connecticut, completing her studies in 2009. Her academic background provides a strong foundation for her expertise in inflammation and immuno-oncology.
Background
Christine Bowman has a diverse professional background in the life sciences. She began her career as a PhD Candidate at Albert Einstein College of Medicine from 2009 to 2013. Following her doctoral studies, she worked as a Postdoctoral Research Scientist at Columbia University from 2013 to 2015. She then joined Regeneron Pharmaceuticals, Inc. as a Scientist for 11 months in 2015-2016 before moving to her current role at Arcus Biosciences.
Achievements
Christine Bowman has co-authored a study on the inhibition of CD39, which resulted in elevated ATP and activation of myeloid cells to promote anti-tumor immunity. This research was presented at the American Association for Cancer Research (AACR) in 2022. Additionally, she presented her findings on the inhibition of CD39 to promote anti-tumor immune responses at Immuno US 2023, showcasing her contributions to the field of immuno-oncology.